Redhill Biopharma Ltd.
Symbol: RDHL (NASDAQ)
1.67
▼ (-1.77%) -0.030
Company Description:
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Key Stats
- Today's Open: $1.72
- Today's High: $1.725
- Today's Low: $1.635
- Today's Volume: 27.84K
- Yesterday Close: $1.7001
- Yesterday High: $1.7052
- Yesterday Low: $1.6553
- Yesterday Volume: 36.77K
- Last Min Volume: 7
- Last Min High: $1.67
- Last Min Low: $1.67
- Last Min VWAP: $1.67
Company Profile
- Name: Redhill Biopharma Ltd.
- Website: https://www.redhillbio.com
- Listed Date: 2013-01-07
- Location: ,
- Market Status: Active
- CIK Number: 0001553846
- SIC Code:
- SIC description:
- Market Cap: $5.63M
- Round Lot: 100
- Outstanding Shares: 3.33M
- Asset Type: ADRC
RECENT FILINGS FOR RDHL
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-09 | EFFECT | View |
| 2025-09-09 | EFFECT | View |
| 2025-09-05 | POS AM | View |
| 2025-09-05 | POS AM | View |
| 2025-09-05 | 6-K/A | View |
| 2025-09-05 | 6-K | View |
| 2025-08-20 | 6-K | View |
| 2025-08-18 | 6-K | View |
| 2025-08-14 | 6-K | View |
| 2025-07-21 | 6-K | View |
| 2025-07-02 | EFFECT | View |
| 2025-07-02 | 424B3 | View |
| 2025-07-01 | 6-K | View |
| 2025-06-30 | CORRESP | View |
| 2025-06-30 | UPLOAD | View |
| 2025-06-25 | F-1 | View |
| 2025-06-25 | 6-K | View |
| 2025-05-27 | 6-K | View |
| 2025-05-19 | 6-K | View |
| 2025-05-13 | 6-K | View |
Latest News on RDHL